Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.
| Revenue (Most Recent Fiscal Year) | $332.07M |
| Net Income (Most Recent Fiscal Year) | $18.25M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 67.83 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.99 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.51 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 24.13 |
| Pre-Tax Margin (Trailing 12 Months) | -2.96% |
| Net Margin (Trailing 12 Months) | -2.73% |
| Return on Equity (Trailing 12 Months) | 2.37% |
| Return on Assets (Trailing 12 Months) | 2.03% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.85 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.69 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.02 |
| Inventory Turnover (Trailing 12 Months) | 8.80 |
| Book Value per Share (Most Recent Fiscal Quarter) | $16.28 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.15 |
| Earnings per Share (Most Recent Fiscal Year) | $0.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.35 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 29.01M |
| Free Float | 27.12M |
| Market Capitalization | $688.66M |
| Average Volume (Last 20 Days) | 0.26M |
| Beta (Past 60 Months) | 1.13 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.60% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |